RTP Mobile Logo
Oncology Tumor Panel Series: Part 4 — Colorectal Cancer
Released August 2015

Video excerpts from the fourth in a series of 5 integrated symposia held at the 2015 ONS Annual Congress. Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Axel Grothey, Ms Jessica Mitchell and Ms Tammy Triglianos. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of colorectal cancer (CRC).

    OVERVIEW OF ACTIVITY
    Cancer of the colon and rectum is the fourth most frequently diagnosed cancer and the second most common cause of death among all neoplasms in the United States, accounting for approximately 8% of all cancer deaths. Current therapeutic management of colorectal cancer (CRC) is dependent on tumor stage at the time of initial diagnosis, status of surgical margins, patient performance status, age, prior treatment exposure and sites of metastasis for those with disease recurrence or de novo advanced cancer. Although these variables are helpful in guiding selection of treatment, the introduction of novel biomarkers, multigene signatures and molecular-targeted systemic agents has significantly refined the clinical algorithm such that individualized therapeutic approaches have become the standard. The availability of multiple recently approved treatment options with novel and complex mechanisms of action reinforces the pivotal position of nurses as caregivers, communicators and educators, as they play an integral role in the successful delivery of systemic anticancer therapy and the preservation of patient physical and psychosocial well-being.

    These video proceedings from the fourth part of a 5-part integrated CNE curriculum originally held at the 2015 ONS Annual Congress feature discussions with leading CRC cancer investigators and their nursing counterparts regarding actual patient cases and recent clinical research findings affecting the optimal therapeutic and supportive care for each patient scenario.


    PURPOSE STATEMENT
    By providing information on the latest research developments in the context of expert perspectives, this CNE activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with CRC.

    LEARNING OBJECTIVES

    • Apply existing and emerging research data to the therapeutic and supportive care of patients with metastatic CRC (mCRC).
    • Describe the clinical impact of and toxicities associated with commonly used systemic therapies for mCRC.
    • Develop an evidence-based algorithm for the prevention and amelioration of side effects associated with chemotherapeutic and biologic agents used in the management of mCRC.
    • Use case-based learning to facilitate improved counseling for patients.
    • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with mCRC to improve clinical and quality-of-life outcomes.

    ACCREDITATION STATEMENT

    CNE credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CNE credit is no longer available for this issue

    FOR SUCCESSFUL COMPLETION
    This is a video CNE program.

    CNE credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Tanios Bekaii-Saab, MD
    Section Chief, Gastrointestinal Oncology
    Chair, OSUCCC Gastrointestinal Disease Research Group
    Professor of Medicine and Pharmacy
    The Ohio State University — James Cancer Hospital
    Columbus, Ohio

    Consulting Agreements: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Lilly, Pfizer Inc, Taiho Oncology Inc; Contracted Research: Oncolytics Biotech Inc; Other Remunerated Activities: Exelixis Inc, Polaris Group.

    Axel Grothey, MD
    Professor of Oncology
    Department of Medical Oncology
    Mayo Clinic
    Rochester, Minnesota

    Contracted Research: Bayer HealthCare Pharmaceuticals, Eisai Inc, Genentech BioOncology, Lilly, Pfizer Inc, Sanofi.

    Jessica Mitchell, APRN, CNP, MPH
    Certified Nurse Practitioner
    GI Medical Oncology
    Mayo Clinic
    Rochester, Minnesota

    No real or apparent conflicts of interest to disclose.

    Tammy Triglianos, RN, MS, APRN-BC, AOCNP
    GI Oncology Nurse Practitioner
    Lineberger Comprehensive Cancer Center at
    The University of North Carolina
    Chapel Hill, North Carolina

    No real or apparent conflicts of interest to disclose.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: August 2015
    Expiration date: August 2016

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch video
(WiFi is recommended for best performance):